Oral Biologics And Biosimilars Market - By Therapeutic Mechanism (Tumor Necrosis Factor-Alpha Inhibitors, Lymphocyte Modulators, Interleukin Inhibitors, GPCR (insulin, growth hormone, parathyroid hormone) Modulators, Immunostimulants, Others), By Disease (Diabetes, Arthritis & Chron`s Disease, Cancer, Infectious Diseases, Other Autoimmune Diseases, Others Diseases), By Molecule Type (Vaccines, Proteins & Peptides, Monoclonal Antibodies, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region, Opportunities And Strategies - Global Forecast To 2030

Starting Price : $ 4000.00 $3200.00 | Pages : 317 | Published : August 2020 | SKU CODE : o&s155 | Format :

Request Sample

Oral Biologics & Biosimilars Market Definition

The oral biologics and biosimilars market consist of sales of oral biologics and biosimilar products and related services used to treat chronic diseases such as diabetes, arthritis, and cancer.  

Biologics are drugs made from living cells using highly complex technology, while biosimilars are biological products which are being produced to be identical to a biologic already approved, known as reference drugs. Biosimilars should have similar safety and efficacy compared to the reference biologic product. The oral biologics and biosimilar market comprise of biologics and biosimilar drugs through oral delivery route, for the treatment of chronic diseases.

Oral Biologics & Biosimilars Market Size

The global oral biologics and biosimilars market reached a value of nearly $3,076.1 million in 2019, having grown at a compound annual growth rate (CAGR) of 6.5% since 2015, and is expected to grow at a CAGR of 17.1% to nearly $5,787.9 million by 2023. Also, the market is expected to growth to $8,687.7 million in 2025 at a CAGR of 22.5% and to $23,585.5 million in 2030 at a CAGR of 22.1%.   Growth in the historic period resulted from increased collaboration and partnerships between market players for better insights, increased need for immunology, increased demand due for cost-effective manufacturing process, aging population, government initiatives, and the ability to command high prices. Factors that negatively affected growth in the historic period were lack of awareness on biosimilars among primary care physicians and specialists, difficulty in manufacturing biologics and pricing pressures from regulators.

Going forward, robust research and development activities for development of oral biologics, lean towards pills over injections, adoption of unhealthy lifestyles, technological advances, ease of use of oral biologics, increase in healthcare access, reimbursement of biologics, rise in biosimilars, and rising prevalence of chronic diseases are expected to drive the market. Higher supervision during clinical studies and stringent regulations related to biosimilar approvals, prolonged production and approval time, difficulties in pricing, nomenclature challenges are major factors that could hinder the growth of the oral biologics and biosimilars market in the future.

Oral Biologics & Biosimilars Market Drivers

The key drivers of the oral biologics & biosimilars market include:

Technological Advances

Technology is expected to be a continued driver of market growth during this period. An area of particular development is likely to be physiology simulation modeling. Markets such as this one will benefit from the greater efficiencies offered by developments in this area. For example, Eli Lilly and Pfizer have adopted Amazon’s Elastic Compute Cloud (EC2) platform to conduct simulation models in early drug discovery that have been operational within hours, whereas traditional models would have taken weeks to conduct simulations. The Open Innovation Drug Discovery program is another initiative by Lilly to enhance the research and development of biologics.

Oral Biologics & Biosimilars Market Restraints

The key restraints on the oral biologics & biosimilars market include:

High Stringency And Low Turnover For Clinical Trials  

For pharmaceutical drugs, clinical studies such as the pharmacokinetics - pharmacodynamics (PK-PD) studies can be carried out on healthy individuals, if it can be safely administered to the healthy population. PK studies determine the time the drug takes to get absorbed, distributed, metabolized, and excreted within the body, and PD studies determine the biochemical and physiological effect of the drug. However, for biological drugs, there are some key considerations regarding the selection of healthy individuals. This is mainly because healthy individuals may have a higher immunogenic response than the population with the disease, and sometimes the PK of the reference product is altered when administered to a healthy individual. This results in unreliable clinical data. Such hindrances may stall the progress of biological drugs.

Oral Biologics & Biosimilars Market Trends

Major trends influencing the oral biologics & biosimilars market include:

Revised FDA Regulations To Facilitate Biologics Drug Development

The US Food and Drug Administration (FDA) has revised its regulations to eliminate outdated biologics requirements, thus allowing drug manufacturers to employ new manufacturing technologies and testing capabilities. Standard preparations (standard solutions containing a precisely known concentration of an element), which help to ensure safety, purity and potency of biologics, can now be obtained from sources other than the FDA’s Center for Biologics Evaluation and Research (CBER), or can be developed internally by the biologics license applicant. The FDA has also removed a rule (Section 610.21 of FDA code) which specifies minimal potency limits to be met for certain antibodies and antigens. In addition, the FDA is also updating regulations (Section 610.53 of FDA code) regarding storage periods and storage conditions for biologics. These amendments in regulations are expected to increase regulatory flexibility by allowing the pharmaceutical industry and the FDA to incorporate current scientific technologies in the manufacture of licensed biological products.

The average yearly number of new drug approvals was 25 from 2000 to 2009, and 41 from 2010 to 2018. The new biologic product approvals increased from a median of 5 from 2000 to 2013, to 12 from 2014 to 2018.

Shift From Small Molecules to Biologics

Pharmaceutical companies are shifting towards large molecules and biologics for drug development.   Pharma companies had focused on small molecules for decades, but the rate of innovation in that field has slowed dramatically, leading to the shift towards biologics. The unmet needs with respect to chronic disease therapies help drive pharmaceutical companies to innovate and develop biologic molecules. For instance, in 2018, the Center for Drug Evaluation and Research (CDER) approved 29% of new molecular entity (NME) approvals for biologics compared to 26% in 2017 and 11% in 2013. This shift also increases the number of approvals for oral biologics.

Opportunities And Recommendations In The Oral Biologics & Biosimilars Market

Opportunities – The top growth potential in the oral biologics and biosimilars market by therapeutic mechanism will arise in Others (Interferons, Opioid receptors, Calcitonin receptor etc) market, which will gain $1,606.8 million of global annual sales by 2023. Vaccines and insulin products will drive the growth of these market segments. The top growth potential in the oral biologics and biosimilars market by disease will arise in the diabetes market, which will gain $1,865.5 million of global annual sales by 2030. By molecule type, Proteins & Peptides will have high market share and potential with annual sales of $15804, by 2030. The top growth potential in the oral biologics and biosimilars market by distribution channel will arise in the hospital pharmacies market, which will gain $1,770.9 million of global annual sales by 2030. The oral biologics and biosimilars market size will gain the most in USA at $1,423.2 million.

Market-trend-based strategies for the oral biologics and biosimilars market include invest in the oral biologics market to benefit from potentially strong profit margins, shift to biologics, as the innovation rate is increasing in that field, develop microneedle injectors-based drugs to increase the bioavailability and eliminate side effects of subcutaneous route. Player-adopted strategies in the oral biologics and biosimilars industry include strengthening oral biologics business with strategic collaborations, and through new launches and approvals, developing and commercializing new therapies for the treatment of patients with food allergies.

Recommendations – To take advantage of the opportunities, the business research company recommends the oral biologics and biosimilars companies to focus on strategic alliances for research & development, focus on expanding through collaborations, expand in emerging markets, consider providing biologics at a considerably lower price and manufacturers should create awareness regarding the benefits and cost effectiveness of biosimilars.

Oral Biologics & Biosimilars Market Segmentation

The oral biologics & biosimilars market is segmented by therapeutic mechanism, disease, molecule type, distribution channel and by geography.?
By Therapeutic Mechanism - The oral biologics & biosimilars market can be segmented by therapeutic mechanism
    • a. Tumor Necrosis Factor-Alpha Inhibitors
    • b. Lymphocyte Modulators
    • c. Interleukin Inhibitors
    • d. GPCR (insulin, growth hormone, parathyroid hormone) Modulators
    • e. Immunostimulants
    • f. Others
The others (Interferons, Opioid receptors, Calcitonin receptor) was the largest segment of the oral biologics and biosimilars market by therapeutic mechanism, accounting for $676.1 million of the total market in 2019.
By Disease –? The oral biologics & biosimilars market can be segmented by disease
    • a. Diabetes
    • b. Arthritis & Chron`s Disease
    • c. Cancer
    • d. Infectious Diseases
    • e. Other Autoimmune Diseases
    • f. Others Diseases
The infectious diseases was the largest segment of the oral biologics and biosimilars market by disease, accounting for $2,305.6 million or 74.9% of the total market in 2019 and this market is expected to grow at a CAGR of 7.1% during 2019-2023. The diabetes market is expected to be the fastest-growing segment going forward at a CAGR of 82.6%.
By Molecule Type –? The Oral Biologics & Biosimilars market can be segmented by molecule
    • a. Vaccines
    • b. Proteins & Peptides
    • c. Monoclonal Antibodies
    • d. Others
The vaccines was the largest segment of the oral biologics and biosimilars market by molecule type, accounting for $2,305.6 million or 74.9% of the total market in 2019 and this market is expected to grow at a CAGR of 7.1% during 2019-2023. The proteins & peptides market is expected to be the fastest-growing segment going forward at a CAGR of 38.0%.
By Distribution Channel–? The oral biologics & biosimilars market can be segmented by distribution channel
    • a. Hospital Pharmacies
    • b. Retail Pharmacies
    • c. Online Pharmacies
The hospital pharmacies was the largest segment of the oral biologics and biosimilars market by distribution channel, accounting for $1,891.3 million or 61.5% of the total market in 2019 and this market is expected to grow at a CAGR of 18.3% during 2019-2023. The online pharmacies distribution channel is expected to be the fastest-growing segment going forward at a CAGR of 25.0%.
By Geography-?The Oral Biologics & Biosimilars market is segmented into
    • o North America
      • USA
    • o Western Europe
      • UK
      • Germany
      • France
    • o Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • Indonesia
      • South Korea
    • o Eastern Europe
      • Russia
    • o South America
      • Brazil
    • o Middle East
    • o Africa
North America was the largest region in the oral biologics and biosimilars market, accounting for 46.2% of the global market in 2019. It was followed by Asia Pacific, Western Europe and the other regions. Going forward, the fastest growing regions in the oral biologics and biosimilars market will be Western Europe and North America, where growth will be at CAGRs of 20.3% and 18.9% respectively from 2019-2023.

Oral Biologics & Biosimilars Competitive Landscape

Major Competitors are:
    • • Merck & Co
    • • GlaxoSmithKline
    • • Novo Nordisk
    • • ALK-Abello A/S
    • • Aimmune Therapeutics, Inc.
Other Competitors Include:
    • • Henlius
    • • Innovent Biologics
    • • Bio-Thera
    • • Hisun Pharma
    • • 3SBio
    • • Beijing ShuangLu Pharmaceuticals
    • • Qilu Pharmaceutical
    • • Shanghai Fosun Pharmaceuticals
    • • Biocon
    • • Mylan
    • • Dr Reddys
    • • Kyowa Hakko Kirin
    • • Takeda
    • • Mitsubishi Tanabe
    • • AGC Biologics
    • • BiosanaPharma
    • • AstraZeneca
    • • Bayer
    • • Boehringer Ingelheim
    • • GlaxoSmithKline
    • • Sanofi
    • • Microgen
    • • Geropharm
    • • Valenta
    • • NovaMedica
    • • SynBio
    • • Roche
    • • Rani Therapeutics
    • • Eli Lilly and Company
    • • Emisphere Technologies, Inc
    • • Enteris BioPharma
    • • Allena Pharmaceuticals
    • • Abbvie
    • • Johnson & Johnson
    • • Biogen Inc.
    • • Pfizer Inc
    • • Ache
    • • Eurofarma
    • • Novartis
    • • Teva Pharmaceuticals
    • • Oramed Pharmaceuticals
    • • Entera Bio
    • • Julphar
    • • Hikma Pharmaceuticals
    • • Altis Biologics
    • • Cipla Medpro South Africa
    • • Sanofi Genzyme

  1. 1. Oral Biologics & Biosimilars Market Executive Summary
  2. 2. Table of Contents
  3. 3. List of Figures
  4. 4. List of Tables
  5. 5. Report Structure
  6. 6. Introduction
    • 6.1.1. Segmentation By Geography
    • 6.1.2. Segmentation By Disease
    • 6.1.3. Segmentation By Molecule Type
    • 6.1.4. Segmentation By Therapeutic Mechanism
    • 6.1.5. Segmentation By Distribution Channel
  7. 7. Oral Biologics & Biosimilars Market Characteristics
    • 7.1. Market Definition
    • 7.2. Market Segmentation By Disease
      • 7.2.1. Diabetes
      • 7.2.2. Arthritis and Crohn’s Disease
      • 7.2.3. Cancer
      • 7.2.4. Infectious Disease
      • 7.2.5. Other Autoimmune Disease
      • 7.2.6. Other Diseases
    • 7.3. Market Segmentation By Molecule Type
      • 7.3.1. Vaccines
      • 7.3.2. Monoclonal Antibodies
      • 7.3.3. Proteins and Peptides
      • 7.3.4. Others
    • 7.4. Market Segmentation By Therapeutic Mechanism
      • 7.4.1. Lymphocyte Modulators
      • 7.4.2. Interleukin Inhibitors
      • 7.4.3. Tumor Necrosis Factor-Alpha Inhibitors
      • 7.4.4. Immunostimulants
      • 7.4.5. GPCR Modulators
      • 7.4.6. Others
    • 7.5. Market Segmentation By Distribution Channel
      • 7.5.1. Hospital Pharmacies
      • 7.5.2. Retail Pharmacies
      • 7.5.3. Online Pharmacies
  8. 8. Oral Biologics And Biosimilars Market, Supply Chain Analysis
    • 8.1. Raw Material Suppliers
    • 8.2. Contract Research Organization (CRO)
    • 8.3. Oral Biologics And Biosimilars Manufacturers
      • 8.3.1. Drug Discovery
      • 8.3.2. Preclinical And Clinical Trials
      • 8.3.3. Patents Upon Discovery And Approval
      • 8.3.4. Drug Manufacturing
    • 8.4. Contract Manufacturing Organization (CMO)
    • 8.5. Wholesalers/Distributors
    • 8.6. Retailers (Pharmacies) And Hospitals
    • 8.7. End-Users
  9. 9. Oral Biologics & Biosimilars Market Product Analysis – Product Examples
  10. 10. Oral Biologics & Biosimilars Market, Product Pipeline Analysis
  11. 11. Oral Biologics and Biosimilars Market Customer Information
    • 11.1. Knowledge Of Biosimilars And Its Difference From Generic Drugs
    • 11.2. Patients’ Perspectives Concerning Biosimilars
    • 11.3. Policies Implemented For Pricing Biosimilar Medicines In Different Countries
    • 11.4. Patients Ready For Cost-saving Biosimilars
    • 11.5. Physicians’ Knowledge And Attitudes Towards Biosimilars In Russia
    • 11.6. Oral Version Of Biologics Could Improve Patient Medication Adherence
    • 11.7. Canadian Physicians Are Familiar With Biosimilars But Lack Understanding
  12. 12. Oral Biologics & Biosimilars Market Trends And Strategies
    • 12.1. Revised FDA Regulations To Facilitate Biologics Drug Development
    • 12.2. Higher Profit Margins For Biologics
    • 12.3. Shift From Small Molecules to Biologics
    • 12.4. Microneedle Pills
    • 12.5. New Insulin Biosimilars
    • 12.6. Robust Research & Development
    • 12.7. Large Number Of Strategic Partnerships
    • 12.8. Extensive Use In Treatment Of Cancer, Diabetes And Other Autoimmune Diseases
    • 12.9. Increase In Comfort & Compliance By Patients
  13. 13. Impact Of Covid-19 On Oral Biologics And Biosimilars Market R&D Funding
  14. 14. Global Oral Biologics & Biosimilars Comparative Analysis Of Overall Biologics & Oral Biologics
  15. 15. Global Oral Biologics & Biosimilars Rise & Evolution
    • 15.1. Rise/Evolution Of Oral Biologics And Biosimilars
    • 15.2. 2006-2015
    • 15.3. 2017- Present Day
  16. 16. Oral Biologics & Biosimilars Companies’ Investment In Research And Development
    • 16.1. Catalent Invested $214 Million To Improve Biologics And Oral Delivery Capabilities
    • 16.2. TrueNorth Invested INR 536 Crore In Biocon Biologics
    • 16.3. Fujifilm To Invest $928 Million To Expand Its Danish Biologics Production Facility
  17. 17. Major Oral Biologics & Biosimilars Developments By Disease
    • 17.1. Diabetes
    • 17.2. Cancer
    • 17.3. Arthritis
    • 17.4. Gastro Intestinal Disorders
    • 17.5. Allergic Reactions
  18. 18. Global Oral Biologics & Biosimilars Market Size And Growth
    • 18.1. Market Size
    • 18.2. Historic Market Growth, 2015 – 2019, Value ($ Million)
      • 18.2.1. Drivers Of The Market 2015 – 2019
      • 18.2.2. Restraints On The Market 2015-19
    • 18.3. Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
      • 18.3.1. Drivers Of The Market 2019 – 2023
      • 18.3.2. Restraints Of The Market 2019-2023
  19. 19. Global Oral Biologics & Biosimilars Market Segmentation
    • 19.1. Global Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
      • 19.1.1. Infectious Diseases
      • 19.1.2. Diabetes
      • 19.1.3. Other Autoimmune Diseases
      • 19.1.4. Others
      • 19.1.5. Cancer
      • 19.1.6. Arthritis & Chron`s Disease
    • 19.2. Global Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
      • 19.2.1. Vaccines
      • 19.2.2. Proteins & Peptides
      • 19.2.3. Others
      • 19.2.4. mAbs
    • 19.3. Global Oral Biologics & Biosimilars Market, Segmentation By Therapeutic  Mechanism Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
      • 19.3.1. Immunostimulants
      • 19.3.2. Others (Interferons, Opioid receptors, Calcitonin receptor etc)
      • 19.3.3. GPCR (Insulin, Growth Hormone, Parathyroid Hormone)
      • 19.3.4. TNF-Alpha
      • 19.3.5. Lymphocyte Modulators
      • 19.3.6. Interleukin Inhibitors
    • 19.4. Global Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
      • 19.4.1. Hospital Pharmacies
      • 19.4.2. Retail Pharmacies
      • 19.4.3. Online Pharmacies
  20. 20. Oral Biologics & Biosimilars Market, Regional And Country Analysis
    • 20.1. Global Oral Biologics & Biosimilars Market, By Region, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
    • 20.2. Global Oral Biologics & Biosimilars Market, By Country, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
  21. 21. Asia-Pacific Oral Biologics & Biosimilars Market
    • 21.1. Asia-Pacific Oral Biologics & Biosimilars Market Overview
      • 21.1.1. Region Information
      • 21.1.2. Market Information
      • 21.1.3. Background Information
      • 21.1.4. Government Initiatives
      • 21.1.5. Regulations
      • 21.1.6. Regulatory Bodies
      • 21.1.7. Major Associations
      • 21.1.8. Taxes Levied
      • 21.1.9. Corporate Tax Structure
      • 21.1.10. Investments
      • 21.1.11. Major Companies
    • 21.2. Asia-Pacific Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 21.3. Asia-Pacific Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 21.4. Asia-Pacific Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
    • 21.5. Asia-Pacific Oral Biologics & Biosimilars Market: Country Analysis
    • 21.6. China Oral Biologics & Biosimilars Market
    • 21.7. China Oral Biologics & Biosimilars Market Overview
      • 21.7.1. Country Information
      • 21.7.2. Market Information
      • 21.7.3. Background Information
      • 21.7.4. Government Initiatives
      • 21.7.5. Regulations
      • 21.7.6. Regulatory Bodies
      • 21.7.7. Major Associations
      • 21.7.8. Taxes Levied
      • 21.7.9. Corporate Tax Structure
      • 21.7.10. Investments
      • 21.7.11. Major Companies
    • 21.8. China Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 21.9. China Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 21.10. China Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
    • 21.11. India Oral Biologics & Biosimilars Market
    • 21.12. India Oral Biologics & Biosimilars Market Overview
      • 21.12.1. Country Information
      • 21.12.2. Market Information
      • 21.12.3. Background Information
      • 21.12.4. Government Initiatives
      • 21.12.5. Regulations
      • 21.12.6. Regulatory Bodies
      • 21.12.7. Major Associations
      • 21.12.8. Taxes Levied
      • 21.12.9. Corporate Tax Structure
      • 21.12.10. Investments
      • 21.12.11. Major Companies
    • 21.13. India Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 21.14. India Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 21.15. India Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
    • 21.16. Japan Oral Biologics & Biosimilars Market
    • 21.17. Japan Oral Biologics & Biosimilars Market Overview
      • 21.17.1. Country Information
      • 21.17.2. Market Information
      • 21.17.3. Background Information
      • 21.17.4. Government Initiatives
      • 21.17.5. Regulations
      • 21.17.6. Regulatory Bodies
      • 21.17.7. Major Associations
      • 21.17.8. Taxes Levied
      • 21.17.9. Corporate Tax Structure
      • 21.17.10. Investments
      • 21.17.11. Major Companies
    • 21.18. Japan Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 21.19. Japan Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 21.20. Japan Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
    • 21.21. Australia Oral Biologics & Biosimilars Market
    • 21.22. Australia Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 21.23. Australia Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 21.24. Australia Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
    • 21.25. Indonesia Oral Biologics & Biosimilars Market
    • 21.26. Indonesia Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 21.27. Indonesia Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 21.28. Indonesia Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
    • 21.29. South Korea Oral Biologics & Biosimilars Market
    • 21.30. South Korea Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 21.31. South Korea Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 21.32. South Korea Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
  22. 22. Western Europe Oral Biologics & Biosimilars Market
    • 22.1. Western Europe Oral Biologics & Biosimilars Market Overview
      • 22.1.1. Region Information
      • 22.1.2. Market Information
      • 22.1.3. Background Information
      • 22.1.4. Government Initiatives
      • 22.1.5. Regulations
      • 22.1.6. Regulatory Bodies
      • 22.1.7. Major Associations
      • 22.1.8. Taxes Levied
      • 22.1.9. Corporate Tax Structure
      • 22.1.10. Investments
      • 22.1.11. Major Companies
    • 22.2. Western Europe Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 22.3. Western Europe Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 22.4. Western Europe Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
    • 22.5. Western Europe Oral Biologics & Biosimilars Market: Country Analysis
    • 22.6. UK Oral Biologics & Biosimilars Market
    • 22.7. UK Oral Biologics & Biosimilars Market Overview
      • 22.7.1. Country Information
      • 22.7.2. Market Information
      • 22.7.3. Background Information
      • 22.7.4. Government Initiatives
      • 22.7.5. Regulations
      • 22.7.6. Regulatory Bodies
      • 22.7.7. Major Associations
      • 22.7.8. Taxes Levied
      • 22.7.9. Corporate Tax Structure
      • 22.7.10. Investments
      • 22.7.11. Major Companies
    • 22.8. UK Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 22.9. UK Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 22.10. UK Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
    • 22.11. Germany Oral Biologics & Biosimilars Market
    • 22.12. Germany Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 22.13. Germany Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 22.14. Germany Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
    • 22.15. France Oral Biologics & Biosimilars Market
    • 22.16. France Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 22.17. France Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 22.18. France Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
  23. 23. Eastern Europe Oral Biologics & Biosimilars Market
    • 23.1. Eastern Europe Oral Biologics & Biosimilars Market Overview
      • 23.1.1. Region Information
      • 23.1.2. Market Information
      • 23.1.3. Background Information
      • 23.1.4. Government Initiatives
      • 23.1.5. Regulations
      • 23.1.6. Regulatory Bodies
      • 23.1.7. Major Associations
      • 23.1.8. Investments
      • 23.1.9. Taxes Levied
      • 23.1.10. Corporate Tax Structure
      • 23.1.11. Major Companies
    • 23.2. Eastern Europe Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 23.3. Eastern Europe Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 23.4. Eastern Europe Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
    • 23.5. Eastern Europe Oral Biologics & Biosimilars Market: Country Analysis
    • 23.6. Russia Oral Biologics & Biosimilars Market
    • 23.7. Russia Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 23.8. Russia Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 23.9. Russia Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
  24. 24. North America Oral Biologics & Biosimilars Market
    • 24.1. North America Oral Biologics & Biosimilars Market Overview
      • 24.1.1. Region Information
      • 24.1.2. Market Information
      • 24.1.3. Background Information
      • 24.1.4. Government Initiatives
      • 24.1.5. Regulations
      • 24.1.6. Regulatory Bodies
      • 24.1.7. Major Associations
      • 24.1.8. Taxes Levied
      • 24.1.9. Corporate Tax Structure
      • 24.1.10. Investments
      • 24.1.11. Major Companies
    • 24.2. North America Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 24.3. North America Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 24.4. North America Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
    • 24.5. North America Oral Biologics & Biosimilars Market: Country Analysis
    • 24.6. USA Oral Biologics & Biosimilars Market
    • 24.7. USA Oral Biologics & Biosimilars Market Overview
      • 24.7.1. Country Information
      • 24.7.2. Market Information
      • 24.7.3. Background Information
      • 24.7.4. Government Initiatives
      • 24.7.5. Regulations
      • 24.7.6. Regulatory Bodies
      • 24.7.7. Major Associations
      • 24.7.8. Tax Levied
      • 24.7.9. Corporate Tax Structure
      • 24.7.10. Investments
      • 24.7.11. Major Companies
    • 24.8. USA Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 24.9. USA Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 24.10. USA Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
  25. 25. South America Oral Biologics & Biosimilars Market
    • 25.1. South America Oral Biologics & Biosimilars Market Overview
      • 25.1.1. Region Information
      • 25.1.2. Market Information
      • 25.1.3. Background Information
      • 25.1.4. Government Initiatives
      • 25.1.5. Regulations
      • 25.1.6. Regulatory Bodies
      • 25.1.7. Major Associations
      • 25.1.8. Taxes Levied
      • 25.1.9. Corporate Tax Structure
      • 25.1.10. Investments
      • 25.1.11. Major Companies
    • 25.2. South America Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 25.3. South America Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 25.4. South America Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
    • 25.5. South America Oral Biologics & Biosimilars Market: Country Analysis
    • 25.6. Brazil Oral Biologics & Biosimilars Market
    • 25.7. Brazil Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 25.8. Brazil Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 25.9. Brazil Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
  26. 26. Middle East Oral Biologics & Biosimilars Market
    • 26.1. Middle East Oral Biologics & Biosimilars Market Overview
      • 26.1.1. Region Information
      • 26.1.2. Market Information
      • 26.1.3. Background Information
      • 26.1.4. Government Initiatives
      • 26.1.5. Regulations
      • 26.1.6. Regulatory Bodies
      • 26.1.7. Major Associations
      • 26.1.8. Taxes Levied
      • 26.1.9. Corporate Tax Structure
      • 26.1.10. Investments
      • 26.1.11. Major Companies
    • 26.2. Middle East Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 26.3. Middle East Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 26.4. Middle East Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
  27. 27. Africa Oral Biologics & Biosimilars Market
    • 27.1. Africa Oral Biologics & Biosimilars Market Overview
      • 27.1.1. Region Information
      • 27.1.2. Market Information
      • 27.1.3. Background Information
      • 27.1.4. Regulations
      • 27.1.5. Regulatory Bodies
      • 27.1.6. Major Associations
      • 27.1.7. Taxes Levied
      • 27.1.8. Corporate Tax Structure
      • 27.1.9. Investments
      • 27.1.10. Major Companies
    • 27.2. Africa Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 27.3. Africa Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 27.4. Africa Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
  28. 28. Global Oral Biologics & Biosimilars Market Competitive Landscape
    • 28.1. Company Profiles
    • 28.2. Merck & Co.
      • 28.2.1. Company Overview
      • 28.2.2. Products And Services
      • 28.2.3. Business Strategy
      • 28.2.4. Financial Overview
    • 28.3. GlaxoSmithKline
      • 28.3.1. Company Overview
      • 28.3.2. Products And Services
      • 28.3.3. Financial Overview
    • 28.4. Novo Nordisk
      • 28.4.1. Company Overview
      • 28.4.2. Products And Services
      • 28.4.3. Business Strategy
      • 28.4.4. Financial Overview
    • 28.5. ALK-Abello A/S
      • 28.5.1. Company Overview
      • 28.5.2. Products And Services
      • 28.5.3. Business Strategy
      • 28.5.4. Financial Overview
    • 28.6. Aimmune Therapeutics, Inc.
      • 28.6.1. Company Overview
      • 28.6.2. Products And Services
      • 28.6.3. Business Strategy
      • 28.6.4. Financial Overview
  29. 29. Key Mergers And Acquisitions In The Oral Biologics & Biosimilars Market
    • 29.1. Abbvie Acquired Allergan
    • 29.2. Takeda Pharmaceutical Company Acquired PvP Biologics, Inc.
    • 29.3. True North Acquired Stake In Biocon Biologics
    • 29.4. Catalent, Inc. Acquired Bristol Myers Squibb’s Oral Dose Manufacturing Facility
    • 29.5. Amgen Acquired Psoriasis Drug Otezla From Celgene
    • 29.6. Amgen’s Acquisition Of Otezla From Celgene
    • 29.7. Bristol Myers Acquired Celgene
    • 29.8. Biocon Acquires Pfizer`s R&D Facility To Boost Biosimilars Development
    • 29.9. Biocon Biologics Acquired R&D Facility From Pfizer Healthcare India
    • 29.10. AstraZeneca Strikes Stock Deal With Daiichi Sankyo
    • 29.11. Takeda Pharmaceutical Company Acquires Shire
    • 29.12. Kashiv Pharma Acquired Adello Biologics
    • 29.13. Stada Acquired Majority Stake In Bioceuticals
    • 29.14. Catalent, Inc. Acquired Cook Pharmica LLC
  30. 30. Oral Biologics & Biosimilars Market Opportunities And Strategies
    • 30.1. Global Oral Biologics & Biosimilars Market In 2023 – Countries Offering Most New Opportunities
    • 30.2. Global Oral Biologics & Biosimilars Market In 2023 – Segments Offering Most New Opportunities
    • 30.3. Global Oral Biologics & Biosimilars Market In 2023 – Growth Strategies
      • 30.3.1. Market Trend Based Strategies
      • 30.3.2. Competitor Strategies
  31. 31. Oral Biologics & Biosimilars Market, Conclusions And Recommendations
    • 31.1. Conclusions
      • 31.1.1. Product
      • 31.1.2. Place
      • 31.1.3. Price
      • 31.1.4. Promotion
  32. 32. Appendix
    • 32.1. Market Data Sources
    • 32.2. Research Methodology
    • 32.3. Currencies
    • 32.4. Research Inquiries
    • 32.5. The Business Research Company
    • 32.6. Copyright and Disclaimer

List Of Tables

    Table 1: Global Oral Biologics & Biosimilars Market, Product Analysis – Product Examples
  • Table 2 :  AstraZeneca - Oral Biologics & Biosimilars Market Pipeline Analysis
  • Table 3 : RANI Therapeutics - Oral Biologics & Biosimilars Market Pipeline Analysis
  • Table 4 : Novo Nordisk A/S - Oral Biologics & Biosimilars Market Pipeline Analysis
  • Table 5 : Oramed Pharmaceuticals - Oral Biologics & Biosimilars Market Pipeline Analysis
  • Table 6 :  Allena Pharmaceuticals - Oral Biologics & Biosimilars Market Pipeline Analysis
  • Table 7 :  ALK-Abelló - Oral Biologics & Biosimilars Market Pipeline Analysis
  • Table 8 :  Others - Oral Biologics & Biosimilars Market Pipeline Analysis
  • Table 9: Global Oral Biologics & Biosimilars Market, Comparative Analysis, Overall Biologics & Oral Biologics
  • Table 10: Global Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 11: Global Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 12: Global Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 13: Global Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 14: Global Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 15: Global Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 16: Global Oral Biologics & Biosimilars Market, Segmentation By Therapeutic  Mechanism Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 17: Global Oral Biologics & Biosimilars Market, Segmentation By Therapeutic Mechanism Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 18: Global Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 19: Global Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 20: Global Oral Biologics & Biosimilars Market, By Region, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 21: Global Oral Biologics & Biosimilars Market, By Region, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 22: Global Oral Biologics & Biosimilars Market, By Country, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 23: Global Oral Biologics & Biosimilars Market, By Country, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 24: Asia Pacific Respiratory Infections And Tuberculosis Disease Prevalence, 2013-2017 94
  • Table 25: Asia Pacific Prevalence Of Asthma, 2014-2017
  • Table 26: Asia Pacific Prevalence Of Diabetes, 2014-2017
  • Table 27: Asia-Pacific Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 28: Asia-Pacific Per Capita Net Disposable Income, 2015-2019, $
  • Table 29:  Asia Pacific Population By Age Group, 2015-2023, Thousands
  • Table 30: Asia-Pacific Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 31: Asia-Pacific Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 32: Asia-Pacific Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 33: Asia-Pacific Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 34: China Respiratory Infections And Tuberculosis Disease Prevalence, 2013-2017 110
  • Table 35: China Prevalence Of Asthma, 2014-2017
  • Table 36: China Prevalence Of Diabetes, 2014-2017
  • Table 37: China Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 38: China Per Capita Net Disposable Income, 2015-2019, $
  • Table 39:  China Population By Age Group, 2015-2023, Thousands
  • Table 40: China Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 41: China Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 42: China Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 43: China Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 44: India Respiratory Infections And Tuberculosis Disease Prevalence, 2013-2017
  • Table 45: India Prevalence Of Asthma, 2014-2017
  • Table 46: India Prevalence Of Diabetes, 2014-2017
  • Table 47: India Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 48: India Per Capita Net Disposable Income, 2015-2019, $
  • Table 49:  India Population By Age Group, 2015-2023, Thousands
  • Table 50: India Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 51: India Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 52: India Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 53: India Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 54: Japan Respiratory Infections And Tuberculosis Disease Prevalence, 2013-2017 131
  • Table 55: Japan Prevalence Of Asthma, 2014-2017
  • Table 56: Japan Prevalence Of Diabetes, 2014-2017
  • Table 57: Japan Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 58: Japan Per Capita Net Disposable Income, 2015-2019, $
  • Table 59:  Japan Population By Age Group, 2015-2023, Thousands
  • Table 60: Japan Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 61: Japan Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 62: Japan Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 63: Japan Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 64: Australia Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 65: Australia Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 66: Australia Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 67: Australia Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 68: Indonesia Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 69: Indonesia Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 70: Indonesia Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 71: Indonesia Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 72: South Korea Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 73: South Korea Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 74: South Korea Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 75: South Korea Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 76: Western Europe Respiratory Infections And Tuberculosis Disease Prevalence, 2013-2017
  • Table 77: Western Europe Prevalence Of Asthma, 2014-2017
  • Table 78: Western Europe Prevalence Of Diabetes, 2013-2017
  • Table 79: Western Europe Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 80: Western Europe Per Capita Net Disposable Income, 2015-2019, $
  • Table 81:  Western Europe Population By Age Group, 2015-2023, Thousands
  • Table 82: Western Europe Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 83: Western Europe Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 84: Western Europe Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 85: Western Europe Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 86: UK Respiratory Infections And Tuberculosis Disease Prevalence, 2013-2017
  • Table 87: UK Prevalence Of Diabetes, 2013-2017
  • Table 88: UK Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 89: UK Per Capita Net Disposable Income, 2015-2019, $
  • Table 90:  UK Population By Age Group, 2015-2023, Thousands
  • Table 91: UK Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 92: UK Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 93: UK Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 94: UK Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 95: Germany Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 96: Germany Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 97: Germany Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 98: Germany Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 99: France Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 100: France Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 101: France Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 102: France Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 103: Eastern Europe Respiratory Infections And Tuberculosis Disease Prevalence, 2013-2017
  • Table 104: Eastern Europe Prevalence Of Asthma, 2014-2017
  • Table 105: Eastern Europe Prevalence Of Diabetes, 2014-2017
  • Table 106: Eastern Europe Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 107:  Eastern Europe Population By Age Group, 2015-2023, Thousands
  • Table 108: Eastern Europe Per Capita Net Disposable Income, 2015-2019, $
  • Table 109: Eastern Europe Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 110: Eastern Europe Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 111: Eastern Europe Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 112: Eastern Europe Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 113: Russia Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 114: Russia Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 115: Russia Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 116: Russia Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 117: North America Respiratory Infections And Tuberculosis Disease Prevalence, 2013-2017
  • Table 118: North America Prevalence Of Asthma, 2014-2017
  • Table 119: North America Prevalence Of Diabetes, 2014-2017
  • Table 120: North America Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 121: North America Per Capita Net Disposable Income, 2015-2019, $
  • Table 122:  North America Population By Age Group, 2015-2023, Thousands
  • Table 123: North America Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 124: North America Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 125: North America Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 126: North America Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 127: USA Respiratory Infections And Tuberculosis Disease Prevalence, 2013-2017 231
  • Table 128: USA Prevalence Of Asthma, 2014-2017
  • Table 129: USA Prevalence Of Diabetes, 2014-2017
  • Table 130: USA Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 131: USA Per Capita Net Disposable Income, 2015-2019, $
  • Table 132:  USA Respiratory Masks (N95 Respirators, Surgical Masks, And Others) Market, Population By Age Group, 2015-2023, Thousands
  • Table 133: USA Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 134: USA Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 135: USA Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 136: USA Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 137: South America Respiratory Infections And Tuberculosis Disease Prevalence, 2013-2017
  • Table 138: South America Prevalence Of Asthma, 2014-2017
  • Table 139: South America Prevalence Of Diabetes, 2013-2017
  • Table 140: South America Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 141:  South America Population By Age Group, 2015-2023, Thousands
  • Table 142: South America Per Capita Net Disposable Income, 2015-2019, $
  • Table 143: South America Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 144: South America Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 145: South America Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 146: South America Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 147: Brazil Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 148: Brazil Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 149: Brazil Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 150: Brazil Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 151: Middle East Respiratory Infections And Tuberculosis Disease Prevalence, 2013-2017
  • Table 152: Middle East Prevalence Of Diabetes, 2014-2017
  • Table 153: Middle East Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 154: Middle East Per Capita Net Disposable Income, 2015-2019, $
  • Table 155:  Middle East Population By Age Group, 2015-2023, Thousands
  • Table 156: Middle East Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 157: Middle East Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 158: Middle East Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 159: Middle East Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 160: Africa Respiratory Infections And Tuberculosis Disease Prevalence, 2013-2017
  • Table 161: Africa Prevalence Of Diabetes, 2013-2017
  • Table 162: Africa Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 163: Africa Per Capita Net Disposable Income, 2015-2019, $
  • Table 164:  Africa Population By Age Group, 2015-2023, Thousands
  • Table 165: Africa Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 166: Africa Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 167: Africa Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 168: Africa Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 169: Global Oral Biologics And Biosimilars Market, Key Competitor Estimated Market Shares, 2019, Percentage (%)
  • Table 170: Merck & Co. – Financial Performance, 2015-2019, $ Billion
  • Table 171: GlaxoSmithKline – Financial Performance, 2015-2019, $ Billion
  • Table 172: Novo Nordisk – Financial Performance, 2015-2019, $ Billion
  • Table 173 : ALK-Abello A/S – Financial Performance, $ Billion
  • Table 174: Global Oral Biologics & Biosimilars Market Size Gain ($ Million), 2019 – 2023, By Country
  • Table 175: Global Oral Biologics & Biosimilars Market Size Gain ($ Million), Segmentation By Disease, 2019 – 2023
  • Table 176: Global Oral Biologics & Biosimilars Market Size Gain ($ Million), Segmentation By Molecule Type, 2019 – 2023
  • Table 177: Global Oral Biologics & Biosimilars Market Size Gain ($ Million), Segmentation By Mechanism Type, 2019 – 2023
  • Table 178: Global Oral Biologics & Biosimilars Market Size Gain ($ Million), Segmentation By Distribution Channel, 2019 – 2023
  • Table 179: Oral Biologics & Biosimilars - Market Data Sources

List Of Figures

    Figure 1: Global Oral Biologics & Biosimilars Market Segmentation By Disease
  • Figure 2: Global Oral Biologics & Biosimilars Market Segmentation By Molecule Type
  • Figure 3: Global Oral Biologics & Biosimilars Market Segmentation By Therapeutic Mechanism
  • Figure 4: Global Oral Biologics & Biosimilars Market Segmentation By Distribution Channel
  • Figure 5: Oral Biologics & Biosimilars Industry, Supply Chain Analysis
  • Figure 6: Global Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 7: Global Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 8: Global Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 9: Global Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 10: Global Oral Biologics & Biosimilars Market, Segmentation By  Therapeutic Mechanism Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 11: Global Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 12: Global Oral Biologics & Biosimilars Market, By Region, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 13: Global Oral Biologics & Biosimilars Market, By Country, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 14: Asia-Pacific Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 15: Asia-Pacific Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 16: Asia-Pacific Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 17: China Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 18: China Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 19: China Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 20: India Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 21: India Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 22: India Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 23: Japan Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 24: Japan Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 25: Japan Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 26: Australia Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 27: Australia Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 28: Australia Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 29: Indonesia Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 30: Indonesia Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 31: Indonesia Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 32: South Korea Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 33: South Korea Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 34: South Korea Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 35: Western Europe Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 36: Western Europe Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 37: Western Europe Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 38: UK Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 39: UK Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 40: UK Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 41: Germany Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 42: Germany Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 43: Germany Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 44: France Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 45: France Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 46: France Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 47: Eastern Europe Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 48: Eastern Europe Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 49: Eastern Europe Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 50: Russia Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 51: Russia Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 52: Russia Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 53: North America Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 54: North America Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 55: North America Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 56: USA Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 57: USA Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 58: USA Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 59: South America Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 60: South America Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 61: South America Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 62: Brazil Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 63: Brazil Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 64: Brazil Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 65: Middle East Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 66: Middle East Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 67: Middle East Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 68: Africa Oral Biologics & Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 69: Africa Oral Biologics & Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 70: Africa Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 71: Global Oral Biologics And Biosimilars Market, Key Competitor Estimated Market Shares, 2019, Percentage (%)
  • Figure 72: Merck & Co. – Financial Performance, 2015-2019, $ Billion
  • Figure 73: GlaxoSmithKline – Financial Performance, 2015-2019, $ Billion
  • Figure 74: Novo Nordisk  – Financial Performance, 2015-2019, $ Billion
  • Figure 75: ALK-Abello A/S – Financial Performance, $ Billion
New Drug Innovations In The Pharmaceuticals Market
Antithrombotic Drugs Are Being Used To Prevent Various Disorders
Increasing Rate Of The Elder Population Is Driving The Ophthalmology Drugs Market
Innovations In The Diabetes Therapies Market
Allergan plc- One Of The Largest Companies In The Global Drugs For Benign Prostatic Hypertrophy Market
Innovation And Development Of Combination Drugs To Enhance Growth Of The Ovarian Cancer Drugs Market
The Global Prostate Cancer Drugs Market Will Reach Around $10 By 2022
Antivirals Are The Largest And Fastest Growing Segment Of The Anti-Infective Drugs Market
Oncology Drugs Market - By Type (Blood Cancer, Breast Cancer, Lung Cancer, Prostate cancer, Colorectal Cancer, Cervical cancer, Kidney cancer, Gastric Cancer, Brain Tumor, Skin Cancer, Ovarian Cancer, Bladder Cancer, Pancreatic Cancer, Thyroid cancer, Others), By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy, Hormonal Therapy), By Distribution Channel (Retail Pharmacies/Drug Stores, Hospital Pharmacies, Others), By Route Of Administration (Oral, Parenteral, Others), By Drug Classification (Branded, Generic), And By Region, Opportunities And Strategies - Global Forecast To 2030
View Report
CAR-T Therapy Market - By Target Antigen (CD19 Therapy, CD22 Therapy, BCMA Therapy, Others), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Others), And By Region, Opportunities And Strategies - Global Forecast To 2030
View Report
Ophthalmology Drugs Market - By Type (Antglaucoma Drugs, Dry Eye Medication And Other Ophthalmological Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores And Others), By Drug Classification (Branded Drugs And Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) And, By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Dry Eye Medication Market - By Type (Aqueous Dry Eye Syndrome, Evaporative Dry Eye Syndrome), By End-User (Hospital Pharmacies, Eye Health Clinics, Retail Pharmacies, Online Pharmacies), By Product Type (Liquid Drops, Gel, Liquid Wipes, Eye Ointment), And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Coronavirus (COVID-19) Current Therapy Market Global Report 2020: COVID 19 Growth And Change
View Report
COVID19 Drug Associated APIs Market Global Report 2020: COVID 19 Growth And Change
View Report
COVID19 Vaccine & Therapeutics Clinical Trial Analysis 2020
View Report
COVID19 Vaccine And Therapeutics Pipeline Analysis 2020
View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)